Patent ID: 7648959

Claim:
A method for treatment of a patient to inhibit or reduce angiogenesis or neovascularization in the eye comprising injecting a therapeutically effective amount of an α v β 3 and/or α v β 5 inhibitor, sufficient to inhibit or reduce angiogenesis or neovascularization in the treated eye, into the sclera layer of the eye of the patient through the location of the exterior surface of the sclera that overlies retinal tissue, wherein the α v β 3 and/or α v β 5 inhibitor is a compound of formula II wherein R 1 is H, alkyl having 1-6 C atoms or benzyl, R 2 is R 10 , CO—R 10 , COOR 6 , COOR 10 , SO 2 R 6 or SO 2 R 10 , R 3 is H, Hal, OA, NHR 10 , N(R 10 ) 2 , —NH-acyl, —O-acyl, CN, NO 2 , OR 10 , SR 10 , R 2 or CONHR 10 , R 4 is H, ═O, ═S, C 1 —C 6 -alkyl or acyl, R 5 is NH 2 , H 2 N—C(═NH) or H 2 N—(C═NH)—NH, where the primary amino groups are optionally provided with conventional amino protective groups or are optionally mono-, di- or trisubstituted by R 10 , CO—R 10 , COOR 10 , SO 2 R 10 , or R 6 , R 7 and R 8 are each independently of one another absent or H, or R 7 and R 8 together are a bond, X, Y are each independently of one another ═N—, —N—, O, S, —CH 2 - or ═C—, with the proviso that at least one of the two definitions X, Y is ═N—, —N—, O or S, W, Z are each independently of one another absent, O, S, NR 1 , C(═O), CONH, NHCO, C(═S)NH, NHC(═S), C(═S), SO 2 NH, NHSO 2 or CA═CA′, R 6 is a mono- or binuclear heterocycle which has 1 to 4 N, O and/or S atoms and is unsubstituted or mono-, di- or trisubstituted by Hal, A, —CO-A, OH, CN, COOH, COOA, CONH 2 , NO 2 , ═NH or ═O R 9 is H, Hal, OA, NHA, NAA′, NHacyl, Oacyl, CN, NO 2 , SA, SOA, SO 2 A, SO 2 Ar or SO 3 H, R 10 is H, A, Ar or aralkyl having 7-14 C atoms, R 11 is H or alkyl having 1-6 C atoms, A, A′ are each independently of one another H or unsubstituted or mono-, di- or tri-R 9 -substituted alkyl or cycloalkyl, each of which has 1-15 C atoms and in which one, two or three methylene groups are optionally replaced by N, O and/or S Ar is an unsubstituted or mono-, di- or tri-A- and/or R 9 -substituted mono- or binuclear aromatic ring system having 0, 1, 2, 3 or 4 N, O and/or S atoms, Hal is F,Cl,Br or I and m, n are each independently of one another 0, 1, 2, 3 or 4, or a physiologically acceptable salt thereof.